Monroid takes the helm at Euro&s Metamax

Share this article:

Euro RSCG Life announced it has hired Cline, Davis & Mann's Julie Monroid to head its MetaMax unit (as first reported in the MM&M Agency Issue, July 2007), which is responsible for much of its Sanofi-Aventis business.

Monroid, who was SVP, group managing director at CDM, becomes EVP, managing director of MetaMax, reporting to MetaMax president and North American co-CEO Doug Burcin. At CDM, she led sizable accounts on Pfizer's Viagra and Relpax and Novo Nordisk's Levemir, NovoLog Mix 70/30, NovoLog and FlexPen -- experience sure to come in handy on Sanofi-Aventis' diabetes drugs Lantus and Lovenox, for which MetaMax handles professional advertising.

Euro RSCG Life reorganized its senior leadership in the spring, following the retirement of chairman Ron Pantello and the departure of CEO Jim Metropoulos, who left just several months after the HAVAS network hired him away from Sudler & Hennessey.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...